The latest lymphoma news
A phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma…
The Food and Drug Administration has granted accelerated approval to epcoritamab-bysp for relapsed or refractory…
The risk of developing lymphoma is slightly elevated in inflammatory bowel disease (IBD) and has…
For 30% to 40% of lymphoma patients who receive CAR T therapy, the treatment is a godsend.…
Nearly 90 percent of patients with an aggressive subtype of non-Hodgkin lymphoma had their cancer…
MYC proteins are important regulators of cancer cell growth, proliferation and metabolism through their ability…
Results from a clinical trial conducted by researchers at the National Institutes of Health (NIH)…
A new nuclear medicine therapy can cure human non-Hodgkin lymphoma in an animal model, according…
“Chronochemotherapy” has been gaining key interest in the research community. As the name suggests, the…
On December 22, 2022, the Food and Drug Administration (FDA) granted accelerated approval to mosunetuzumab-axgb…